• 1
    Eckmann CR, Rammelt C & Wahle E (2011) Control of poly(A) tail length. Wiley Interdisciplinary Rev 2, 348361.
  • 2
    Weill L, Belloc E, Bava FA & Mendez R (2012) Translational control by changes in poly(A) tail length: recycling mRNAs. Nat Struct Mol Biol 19, 577585.
  • 3
    Kuhn U & Wahle E (2004) Structure and function of poly(A) binding proteins. Biochim Biophys Acta 1678, 6784.
  • 4
    Mangus DA, Evans MC & Jacobson A (2003) Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol 4, 223.
  • 5
    Ishigaki Y, Li X, Serin G & Maquat LE (2001) Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell 106, 607617.
  • 6
    Wahle E (1991) A novel poly(A)-binding protein acts as a specificity factor in the second phase of messenger RNA polyadenylation. Cell 66, 759768.
  • 7
    Krause S, Fakan S, Weis K & Wahle E (1994) Immunodetection of poly(A) binding protein II in the cell nucleus. Exp Cell Res 214, 7582.
  • 8
    Calado A, Kutay U, Kuhn U, Wahle E & Carmo-Fonseca M (2000) Deciphering the cellular pathway for transport of poly(A)-binding protein II. RNA 6, 245256.
  • 9
    Kerwitz Y, Kuhn U, Lilie H, Knoth A, Scheuermann T, Friedrich H, Schwarz E & Wahle E (2003) Stimulation of poly(A) polymerase through a direct interaction with the nuclear poly(A) binding protein allosterically regulated by RNA. EMBO J 22, 37053714.
  • 10
    Kuhn U, Gundel M, Knoth A, Kerwitz Y, Rudel S & Wahle E (2009) Poly(A) tail length is controlled by the nuclear poly(A)-binding protein regulating the interaction between poly(A) polymerase and the cleavage and polyadenylation specificity factor. J Biol Chem 284, 2280322814.
  • 11
    Apponi LH, Leung SW, Williams KR, Valentini SR, Corbett AH & Pavlath GK (2009) Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. Human Mol Genet 19, 10581065.
  • 12
    Jenal M, Elkon R, Loayza-Puch F, van Haaften G, Kuhn U, Menzies FM, Oude Vrielink JA, Bos AJ, Drost J, Rooijers K et al. (2012) The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 149, 538553.
  • 13
    Beaulieu YB, Kleinman CL, Landry-Voyer AM, Majewski J & Bachand F (2012) Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1. PLoS Gene 8, e1003078.
  • 14
    Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O et al. (1998) Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Gene 18, 164167.
  • 15
    Victor M, Hayes R & Adams RD (1962) Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Eng J Med 267, 12671272.
  • 16
    Ruegg S, Lehky Hagen M, Hohl U, Kappos L, Fuhr P, Plasilov M, Muller H & Heinimann K (2005) Oculopharyngeal muscular dystrophy – an under-diagnosed disorder? Swiss Medical Weekly 135, 574586.
  • 17
    Van Der Sluijs BM, Hoefsloot LH, Padberg GW, Van Der Maarel SM & Van Engelen BG (2003) Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. J Neurol 250, 13071312.
  • 18
    Messaed C, Dion PA, Abu-Baker A, Rochefort D, Laganiere J, Brais B & Rouleau GA (2007) Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy. Neurobiol Dis 26, 546557.
  • 19
    Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Blumen N, Wirguin Y, Khilkevich O, Carasso RL & Korczyn AD (1997) Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul Disord 7 (Suppl 1), S38S40.
  • 20
    Bouchard JP, Brais B, Brunet D, Gould PV & Rouleau GA (1997) Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul Disord 7 (Suppl 1), S22S29.
  • 21
    Kuhn U, Nemeth A, Meyer S & Wahle E (2003) The RNA binding domains of the nuclear poly(A)-binding protein. J Biol Chem 278, 1691616925.
  • 22
    Ge H, Zhou D, Tong S, Gao Y, Teng M & Niu L (2008) Crystal structure and possible dimerization of the single RRM of human PABPN1. Proteins 71, 15391545.
  • 23
    Good PJ, Abler L, Herring D & Sheets MD (2004) Xenopus embryonic poly(A) binding protein 2 (ePABP2) defines a new family of cytoplasmic poly(A) binding proteins expressed during the early stages of vertebrate development. Genesis 38, 166175.
  • 24
    Song J, McGivern JV, Nichols KW, Markley JL & Sheets MD (2008) Structural basis for RNA recognition by a type II poly(A)-binding protein. Proc Natl Acad Sci U S A 105, 1531715322.
  • 25
    Fan X, Dion P, Laganiere J, Brais B & Rouleau GA (2001) Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. Human Mol Genet 10, 23412351.
  • 26
    Smith JJ, Rucknagel KP, Schierhorn A, Tang J, Nemeth A, Linder M, Herschman HR & Wahle E (1999) Unusual sites of arginine methylation in poly(A)-binding protein II and in vitro methylation by protein arginine methyltransferases PRMT1 and PRMT3. J Biol Chem 274, 1322913234.
  • 27
    Fronz K, Otto S, Kolbel K, Kuhn U, Friedrich H, Schierhorn A, Beck-Sickinger AG, Ostareck-Lederer A & Wahle E (2008) Promiscuous modification of the nuclear poly(A)-binding protein by multiple protein-arginine methyltransferases does not affect the aggregation behavior. J Biol Chem 283, 2040820420.
  • 28
    Fronz K, Guttinger S, Burkert K, Kuhn U, Stohr N, Schierhorn A & Wahle E (2011) Arginine methylation of the nuclear poly(A) binding protein weakens the interaction with its nuclear import receptor, transportin. J Biol Chem 286, 3298632994.
  • 29
    Wahle E & Moritz B (2013) Methylation of the nuclear poly(A) binding protein by type I protein arginine methyltransferases – how and why. Biol press. doi: 10.1515/hsz-2013-0121
  • 30
    Keller RW, Kuhn U, Aragon M, Bornikova L, Wahle E & Bear DG (2000) The nuclear poly(A) binding protein, PABP2, forms an oligomeric particle covering the length of the poly(A) tail. J Mol Biol 297, 569583.
  • 31
    Di Giammartino DC, Nishida K & Manley JL (2011) Mechanisms and consequences of alternative polyadenylation. Mol Cell 43, 853866.
  • 32
    de Klerk E, Venema A, Anvar SY, Goeman JJ, Hu O, den Dunnen JT, van der Maarel SM, Raz V & t Hoen PA (2012) Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res 40, 90899101.
  • 33
    Boutet SC, Cheung TH, Quach NL, Liu L, Prescott SL, Edalati A, Iori K & Rando TA (2012) Alternative polyadenylation mediates microRNA regulation of muscle stem cell function. Cell Stem Cell 10, 327336.
  • 34
    Ji Z, Lee JY, Pan Z, Jiang B & Tian B (2009) Progressive lengthening of 3′ untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. Proc Natl Acad Sci U S A 106, 70287033.
  • 35
    Mayr C & Bartel DP (2009) Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673684.
  • 36
    Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, Askarian-Amiri ME, Ru K, Solda G, Simons C et al. (2008) Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res 18, 14331445.
  • 37
    Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A & Bozzoni I (2011) A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147, 358369.
  • 38
    Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL et al. (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 10711076.
  • 39
    Bhattacharjee RB & Bag J (2012) Depletion of nuclear poly(A) binding protein PABPN1 produces a compensatory response by cytoplasmic PABP4 and PABP5 in cultured human cells. PLoS ONE 7, e53036.
  • 40
    Mitchell P, Petfalski E, Shevchenko A, Mann M & Tollervey D (1997) The exosome: a conserved eukaryotic RNA processing complex containing multiple 3′[RIGHTWARDS ARROW]5′ exoribonucleases. Cell 91, 457466.
  • 41
    Benoit B, Mitou G, Chartier A, Temme C, Zaessinger S, Wahle E, Busseau I & Simonelig M (2005) An essential cytoplasmic function for the nuclear poly(A) binding protein, PABP2, in poly(A) tail length control and early development in Drosophila. Develop Cell 9, 511522.
  • 42
    Millevoi S & Vagner S (2010) Molecular mechanisms of eukaryotic pre-mRNA 3′ end processing regulation. Nucleic Acids Res 38, 27572774.
  • 43
    Mandel CR, Bai Y & Tong L (2008) Protein factors in pre-mRNA 3′-end processing. Cell Mol Life Sci 65, 10991122.
  • 44
    Lemieux C & Bachand F (2009) Cotranscriptional recruitment of the nuclear poly(A)-binding protein Pab2 to nascent transcripts and association with translating mRNPs. Nucleic Acids Res 37, 34183430.
  • 45
    Perreault A, Lemieux C & Bachand F (2007) Regulation of the nuclear poly(A)-binding protein by arginine methylation in fission yeast. J Biol Chem 282, 75527562.
  • 46
    Lemay JF, D'Amours A, Lemieux C, Lackner DH, St-Sauveur VG, Bahler J & Bachand F (2010) The nuclear poly(A)-binding protein interacts with the exosome to promote synthesis of noncoding small nucleolar RNAs. Mol Cell 37, 3445.
  • 47
    Mallet PL & Bachand F (2012) A proline-tyrosine nuclear localization signal (Py-Nls) is required for the nuclear import of fission yeast pab2, but not of human pabpn1. Traffic 14, 282294.
  • 48
    Lemieux C, Marguerat S, Lafontaine J, Barbezier N, Bahler J & Bachand F (2011) A pre-mRNA degradation pathway that selectively targets intron-containing genes requires the nuclear poly(A)-binding protein. Mol Cell 44, 108119.
  • 49
    St-Andre O, Lemieux C, Perreault A, Lackner DH, Bahler J & Bachand F (2010) Negative regulation of meiotic gene expression by the nuclear poly(A)-binding protein in fission yeast. J Biol Chem 285, 2785927868.
  • 50
    Yamanaka S, Yamashita A, Harigaya Y, Iwata R & Yamamoto M (2010) Importance of polyadenylation in the selective elimination of meiotic mRNAs in growing S. pombe cells. EMBO J 29, 21732181.
  • 51
    Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR & Ruvkun G (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901906.
  • 52
    Hurschler BA, Harris DT & Grosshans H (2011) The type II poly(A)-binding protein PABP-2 genetically interacts with the let-7 miRNA and elicits heterochronic phenotypes in Caenorhabditis elegans. Nucleic Acids Res 39, 56475657.
  • 53
    Benoit B, Nemeth A, Aulner N, Kuhn U, Simonelig M, Wahle E & Bourbon HM (1999) The Drosophila poly(A)-binding protein II is ubiquitous throughout Drosophila development and has the same function in mRNA polyadenylation as its bovine homolog in vitro. Nucleic Acids Res 27, 37713778.
  • 54
    Tome FM & Fardeau M (1980) Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol 49, 8587.
  • 55
    Zoghbi HY & Orr HT (1999) Polyglutamine diseases: protein cleavage and aggregation. Curr Opin Neurobiol 9, 566570.
  • 56
    Nasrallah IM, Minarcik JC & Golden JA (2004) A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death. J Cell Biol 167, 411416.
  • 57
    Caburet S, Demarez A, Moumne L, Fellous M, De Baere E & Veitia RA (2004) A recurrent polyalanine expansion in the transcription factor FOXL2 induces extensive nuclear and cytoplasmic protein aggregation. J Med Gene 41, 932936.
  • 58
    Scheuermann T, Schulz B, Blume A, Wahle E, Rudolph R & Schwarz E (2003) Trinucleotide expansions leading to an extended poly-L-alanine segment in the poly (A) binding protein PABPN1 cause fibril formation. Protein Sci 12, 26852692.
  • 59
    Lodderstedt G, Hess S, Hause G, Scheuermann T, Scheibel T & Schwarz E (2007) Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1. FEBS J 274, 346355.
  • 60
    Winter R, Kuhn U, Hause G & Schwarz E (2012) Polyalanine-independent conformational conversion of nuclear poly(A)-binding protein 1 (PABPN1). J Biol Chem 287, 2266222671.
  • 61
    Tavanez JP, Calado P, Braga J, Lafarga M & Carmo-Fonseca M (2005) In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. RNA 11, 752762.
  • 62
    Shanmugam V, Dion P, Rochefort D, Laganiere J, Brais B & Rouleau GA (2000) PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. Ann Neurol 48, 798802.
  • 63
    Abu-Baker A, Messaed C, Laganiere J, Gaspar C, Brais B & Rouleau GA (2003) Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Human Mol Genet 12, 26092623.
  • 64
    Wang Q & Bag J (2006) Ectopic expression of a polyalanine expansion mutant of poly(A)-binding protein N1 in muscle cells in culture inhibits myogenesis. Biochem Biophys Res Commun 340, 815822.
  • 65
    Tavanez JP, Bengoechea R, Berciano MT, Lafarga M, Carmo-Fonseca M & Enguita FJ (2009) Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1. PLoS ONE 4, e6418.
  • 66
    Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E & Carmo-Fonseca M (2000) Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Human Mol Genet 9, 23212328.
  • 67
    Corbeil-Girard LP, Klein AF, Sasseville AM, Lavoie H, Dicaire MJ, Saint-Denis A, Page M, Duranceau A, Codere F, Bouchard JP et al. (2005) PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol Dis 18, 551567.
  • 68
    Fan X, Messaed C, Dion P, Laganiere J, Brais B, Karpati G & Rouleau GA (2003) HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. Can J Neurol Sci 30, 244251.
  • 69
    Bao YP, Cook LJ, O'Donovan D, Uyama E & Rubinsztein DC (2002) Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J Biol Chem 277, 1226312269.
  • 70
    Marie-Josee Sasseville A, Caron AW, Bourget L, Klein AF, Dicaire MJ, Rouleau GA, Massie B, Langelier Y & Brais B (2006) The dynamism of PABPN1 nuclear inclusions during the cell cycle. Neurobiol Dis 23, 621629.
  • 71
    Abu-Baker A, Laganiere S, Fan X, Laganiere J, Brais B & Rouleau GA (2005) Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy. Traffic 6, 766779.
  • 72
    Bhattacharjee RB, Zannat T & Bag J (2012) Expression of the poly alanine expansion mutatant of nuclear poly (A) binding protein induces apoptosis via the p53 pathway. Cell Biol Int 36, 697704.
  • 73
    Bao YP, Sarkar S, Uyama E & Rubinsztein DC (2004) Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. J Med Genet 41, 4751.
  • 74
    Chou AH, Lin AC, Hong KY, Hu SH, Chen YL, Chen JY & Wang HL (2011) p53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neurochem Int 58, 145152.
  • 75
    Tsoi H, Lau TC, Tsang SY, Lau KF & Chan HY (2012) CAG expansion induces nucleolar stress in polyglutamine diseases. Proc Natl Acad Sci U S A 109, 1342813433.
  • 76
    Davies JE, Sarkar S & Rubinsztein DC (2006) Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Human Mol Genet 15, 2331.
  • 77
    Megeney LA & Rudnicki MA (1995) Determination versus differentiation and the MyoD family of transcription factors. Biochem Cell Biol 73, 723732.
  • 78
    Relaix F, Montarras D, Zaffran S, Gayraud-Morel B, Rocancourt D, Tajbakhsh S, Mansouri A, Cumano A & Buckingham M (2006) Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol 172, 91102.
  • 79
    Raz V, Routledge S, Venema A, Buijze H, van der Wal E, Anvar S, Straasheijm KR, Klooster R, Antoniou M & van der Maarel SM (2011) Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein. Am J Pathol 179, 19882000.
  • 80
    Anvar SY, t Hoen PA, Venema A, van der Sluijs B, van Engelen B, Snoeck M, Vissing J, Trollet C, Dickson G & Chartier A et al. (2011) Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. Skeletal Muscle 1, 15.
  • 81
    Trollet C, Anvar SY, Venema A, Hargreaves IP, Foster K, Vignaud A, Ferry A, Negroni E, Hourde C, Baraibar MA et al. (2010) Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Human Mol Genet 19, 21912207.
  • 82
    Catoire H, Pasco MY, Abu-Baker A, Holbert S, Tourette C, Brais B, Rouleau GA, Parker JA & Neri C (2008) Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Human Mol Genet 17, 21082117.
  • 83
    Pasco MY, Catoire H, Parker JA, Brais B, Rouleau GA & Neri C (2010) Cross-talk between canonical Wnt signaling and the sirtuin-FoxO longevity pathway to protect against muscular pathology induced by mutant PABPN1 expression in C. elegans. Neurobiol Dis 38, 425433.
  • 84
    Chartier A, Benoit B & Simonelig M (2006) A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J 25, 22532262.
  • 85
    Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM & Simonelig M (2009) Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Human Mol Genet 18, 18491859.
  • 86
    Barbezier N, Chartier A, Bidet Y, Buttstedt A, Voisset C, Galons H, Blondel M, Schwarz E & Simonelig M (2011) Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med 3, 3549.
  • 87
    Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O'Donovan DG & Rubinsztein DC (2005) Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 11, 672677.
  • 88
    Davies JE, Rose C, Sarkar S & Rubinsztein DC (2010) Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci Translational Med 2, 34ra40.
  • 89
    Abmayr SM & Pavlath GK (2012) Myoblast fusion: lessons from flies and mice. Development 139, 641656.
  • 90
    Riddle DL, Blumenthal T, Meyer BJ & Priess JR (1997) Introduction to C. elegans. In C. elegans II 2nd edition (Riddle DL, Blumenthal T, Meyer BJ et al., eds), Chapter 1. Cold Spring Harbor Laboratory. CSHL Press, New York.
  • 91
    Hino H, Araki K, Uyama E, Takeya M, Araki M, Yoshinobu K, Miike K, Kawazoe Y, Maeda Y, Uchino M et al. (2004) Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Human Mol Genet 13, 181190.
  • 92
    Dion P, Shanmugam V, Gaspar C, Messaed C, Meijer I, Toulouse A, Laganiere J, Roussel J, Rochefort D, Laganiere S et al. (2005) Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol Dis 18, 528536.
  • 93
    Boukriche Y, Maisonobe T & Masson C (2002) Neurogenic involvement in a case of oculopharyngeal muscular dystrophy. Muscle Nerve 25, 98101.
  • 94
    Schober R, Kress W, Grahmann F, Kellermann S, Baum P, Gunzel S & Wagner A (2001) Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. Neuropathology 21, 4552.
  • 95
    Blumen SC, Bouchard JP, Brais B, Carasso RL, Paleacu D, Drory VE, Chantal S, Blumen N & Braverman I (2009) Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes. Neurology 73, 596601.
  • 96
    Dubbioso R, Moretta P, Manganelli F, Fiorillo C, Iodice R, Trojano L & Santoro L (2012) Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy. J Neurol 259, 833837.
  • 97
    Mankodi A, Wheeler TM, Shetty R, Salceies KM, Becher MW & Thornton CA (2012) Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy. Neurobiol Dis 45, 539546.
  • 98
    Davies JE, Sarkar S & Rubinsztein DC (2008) Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Human Mol Genet 17, 10971108.
  • 99
    Schroder JM, Klossok T & Weis J (2011) Oculopharyngeal muscle dystrophy: fine structure and mRNA expression levels of PABPN1. Clin Neuropathol 30, 94103.
  • 100
    Perie S, Mamchaoui K, Mouly V, Blot S, Bouazza B, Thornell LE, St Guily JL & Butler-Browne G (2006) Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: therapeutic perspectives of autologous myoblast transplantation. Neuromuscul Disord 16, 770781.
  • 101
    Gidaro T, Negroni E, Perie S, Mirabella M, Laine J, Lacau St Guily J, Butler-Browne G, Mouly V & Trollet C (2013) Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J Neuropathol Exper Neurol 72, 234243.
  • 102
    Ross CA & Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10 (Suppl), S10S17.
  • 103
    Di Zanni E, Bachetti T, Parodi S, Bocca P, Prigione I, Di Lascio S, Fornasari D, Ravazzolo R & Ceccherini I (2012) In vitro drug treatments reduce the deleterious effects of aggregates containing polyAla expanded PHOX2B proteins. Neurobiol Dis 45, 508518.
  • 104
    Uyama E, Tsukahara T, Goto K, Kurano Y, Ogawa M, Kim YJ, Uchino M & Arahata K (2000) Nuclear accumulation of expanded PABP2 gene product in oculopharyngeal muscular dystrophy. Muscle Nerve 23, 15491554.
  • 105
    Berciano MT, Villagra NT, Ojeda JL, Navascues J, Gomes A, Lafarga M & Carmo-Fonseca M (2004) Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus. Human Mol Genet 13, 829838.
  • 106
    Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, MacDonald ME & Gusella JF (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somatic Cell Mol Genet 24, 217233.
  • 107
    Preisinger E, Jordan BM, Kazantsev A & Housman D (1999) Evidence for a recruitment and sequestration mechanism in Huntington's disease. Phil Trans R Soc Lond 354, 10291034.
  • 108
    Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E & MacDonald ME (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Human Mol Genet 9, 27992809.
  • 109
    Bruneau S, Johnson KR, Yamamoto M, Kuroiwa A & Duboule D (2001) The mouse Hoxd13(spdh) mutation, a polyalanine expansion similar to human type II synpolydactyly (SPD), disrupts the function but not the expression of other Hoxd genes. Develop Biol 237, 345353.
  • 110
    Bengoechea R, Tapia O, Casafont I, Berciano J, Lafarga M & Berciano MT (2012) Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy. Neurobiol Dis 46, 118129.
  • 111
    Saudou F, Finkbeiner S, Devys D & Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 5566.
  • 112
    Stromme P, Mangelsdorf ME, Shaw MA, Lower KM, Lewis SM, Bruyere H, Lutcherath V, Gedeon AK, Wallace RH, Scheffer IE et al. (2002) Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Gene 30, 441445.
  • 113
    Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr HT & Zoghbi HY (2008) Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452, 713718.
  • 114
    Renault V, Thornell LE, Eriksson PO, Butler-Browne G & Mouly V (2002) Regenerative potential of human skeletal muscle during aging. Aging Cell 1, 132139.
  • 115
    Conboy IM & Rando TA (2005) Aging, stem cells and tissue regeneration: lessons from muscle. Cell Cycle 4, 407410.
  • 116
    Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, Shkreli M, Delp S, Pomerantz JH, Artandi SE et al. (2010) Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143, 10591071.
  • 117
    Fischer MD, Budak MT, Bakay M, Gorospe JR, Kjellgren D, Pedrosa-Domellof F, Hoffman EP & Khurana TS (2005) Definition of the unique human extraocular muscle allotype by expression profiling. Physiol Genomics 22, 283291.
  • 118
    Porter JD, Israel S, Gong B, Merriam AP, Feuerman J, Khanna S & Kaminski HJ (2006) Distinctive morphological and gene/protein expression signatures during myogenesis in novel cell lines from extraocular and hindlimb muscle. Physiol Genomics 24, 264275.
  • 119
    Pavlath GK, Thaloor D, Rando TA, Cheong M, English AW & Zheng B (1998) Heterogeneity among muscle precursor cells in adult skeletal muscles with differing regenerative capacities. Develop Dynamics 212, 495508.
  • 120
    Sambasivan R, Kuratani S & Tajbakhsh S (2011) An eye on the head: the development and evolution of craniofacial muscles. Development 138, 24012415.